Your browser doesn't support javascript.
loading
G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
Blake, Alexandra; Dragan, Magdalena; Tirona, Rommel G; Hardy, Daniel B; Brackstone, Muriel; Tuck, Alan B; Babwah, Andy V; Bhattacharya, Moshmi.
Afiliación
  • Blake A; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
  • Dragan M; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
  • Tirona RG; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
  • Hardy DB; Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
  • Brackstone M; Lawson Health Research Institute, London, ON, Canada.
  • Tuck AB; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
  • Babwah AV; Lawson Health Research Institute, London, ON, Canada.
  • Bhattacharya M; Department of Obstetrics and Gynecology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.
Sci Rep ; 7: 46525, 2017 04 19.
Article en En | MEDLINE | ID: mdl-28422142
Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor α, progesterone receptor and human epidermal growth factor receptor 2 (HER2). TNBC patients lack targeted therapies, as they fail to respond to endocrine and anti-HER2 therapy. Prognosis for this aggressive cancer subtype is poor and survival is limited due to the development of resistance to available chemotherapies and resultant metastases. The mechanisms regulating tumor resistance are poorly understood. Here we demonstrate that the G protein-coupled kisspeptin receptor (KISS1R) promotes drug resistance in TNBC cells. KISS1R binds kisspeptins, peptide products of the KISS1 gene and in numerous cancers, this signaling pathway plays anti-metastatic roles. However, in TNBC, KISS1R promotes tumor invasion. We show that KISS1 and KISS1R mRNA and KISS1R protein are upregulated in TNBC tumors, compared to normal breast tissue. KISS1R signaling promotes drug resistance by increasing the expression of efflux drug transporter, breast cancer resistance protein (BCRP) and by inducing the activity and transcription of the receptor tyrosine kinase, AXL. BCRP and AXL transcripts are elevated in TNBC tumors, compared to normal breast, and TNBC tumors expressing KISS1R also express AXL and BCRP. Thus, KISS1R represents a potentially novel therapeutic target to restore drug sensitivity in TNBC patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Regulación Neoplásica de la Expresión Génica / Resistencia a Antineoplásicos / Neoplasias de la Mama Triple Negativas / Receptores de Kisspeptina-1 Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Regulación Neoplásica de la Expresión Génica / Resistencia a Antineoplásicos / Neoplasias de la Mama Triple Negativas / Receptores de Kisspeptina-1 Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido